Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

BJUI compass

Showing results (31-40 of 640) with videos related to

Pageof 64
Sort By:
BJUI Compass|October 21, 2022
Management of urachal cancer in pregnancy: A systematic reviewKenneth K Y Chew, Samantha Quah, Madison R Boot, et al.
BJUI Compass|October 21, 2022
Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testingEoin Dinneen, Gregory L Shaw, Roseann Kealy, et al.
BJUI Compass|April 27, 2022
Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patientsYasuhide Miyoshi, Masato Yasui, Sohgo Ttsutsumi, et al.
BJUI Compass|April 27, 2022
A lower psoas muscle index predicts a poorer prognosis in metastatic hormone-naïve prostate cancerGenta Iwamoto, Takashi Kawahara, Toshitaka Miyai, et al.
BJUI Compass|April 27, 2022
Low-Dose-Rate Prostate Brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cureJennifer Uribe, Santiago Uribe-Lewis, Sara Khaksar, et al.
BJUI Compass|April 27, 2022
<i>BJUI Compass</i> 2021 year-end reviewJohn W Davis
BJUI Compass|April 27, 2022
Systematic expression analysis of m<sup>6</sup>A RNA methyltransferases in clear cell renal cell carcinomaLarissa Gundert, Alexander Strick, Felix von Hagen, et al.
BJUI Compass|April 27, 2022
Local versus general anesthesia transperineal prostate biopsy: Tolerability, cancer detection, and complicationsDonnacha Hogan, Abbie Kanagarajah, Henry H Yao, et al.
BJUI Compass|April 27, 2022
BJUI Compass in the COVID eraJohn W Davis
BJUI Compass|April 27, 2022
Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial resultsKevin C Zorn, Mohamed Bidair, Andrew Trainer, et al.
Pageof 64

Showing results (31-40 of 640) with videos related to

Sort By:
Pageof 64
BJUI Compass|October 21, 2022
Management of urachal cancer in pregnancy: A systematic reviewKenneth K Y Chew, Samantha Quah, Madison R Boot, et al.
BJUI Compass|October 21, 2022
Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testingEoin Dinneen, Gregory L Shaw, Roseann Kealy, et al.
BJUI Compass|April 27, 2022
Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patientsYasuhide Miyoshi, Masato Yasui, Sohgo Ttsutsumi, et al.
BJUI Compass|April 27, 2022
A lower psoas muscle index predicts a poorer prognosis in metastatic hormone-naïve prostate cancerGenta Iwamoto, Takashi Kawahara, Toshitaka Miyai, et al.
BJUI Compass|April 27, 2022
Low-Dose-Rate Prostate Brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cureJennifer Uribe, Santiago Uribe-Lewis, Sara Khaksar, et al.
BJUI Compass|April 27, 2022
<i>BJUI Compass</i> 2021 year-end reviewJohn W Davis
BJUI Compass|April 27, 2022
Systematic expression analysis of m<sup>6</sup>A RNA methyltransferases in clear cell renal cell carcinomaLarissa Gundert, Alexander Strick, Felix von Hagen, et al.
BJUI Compass|April 27, 2022
Local versus general anesthesia transperineal prostate biopsy: Tolerability, cancer detection, and complicationsDonnacha Hogan, Abbie Kanagarajah, Henry H Yao, et al.
BJUI Compass|April 27, 2022
BJUI Compass in the COVID eraJohn W Davis
BJUI Compass|April 27, 2022
Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial resultsKevin C Zorn, Mohamed Bidair, Andrew Trainer, et al.
Pageof 64